Clemens B. Caspar

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients

John M. Timmerman, Debra K. Czerwinski, Thomas A. Davis et al. · Blood · 2002 · 542 citations · Full text

Medicine, Immunology, Oncology +16

Tumor-Specific Idiotype Vaccines in the Treatment of Patients With B-Cell Lymphoma — Long-Term Results of a Clinical Trial

Frank J. Hsu, Clemens B. Caspar, Debra K. Czerwinski et al. · Blood · 1997 · 454 citations · Full text

Medicine, Immunology, Oncology +16

Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial

Rolf A. Stahel, Oliver Riesterer, Alexandros Xyrafas et al. · The Lancet Oncology · 2015 · 201 citations

Medicine, Oncology, Surgery +15

Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.

John M. Timmerman, Gita Singh, Gary Hermanson et al. · PubMed · 2002 · 179 citations

Life Sciences, Immunology, Oncology +17